Tag: iShares U.S. Pharmaceuticals ETF

Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Novo Nordisk shares slide after guidance disappoints investors

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways

Small-cap stocks enjoy their best first half in 35 years. Here’s what’s driving it